Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03876106 · ClinicalTrials.gov registry record · Phase 1
A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform Lesions
A Phase 1 study of EGFR Inhibitor Induced Acneiform Lesions, sponsored by Lutris Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 6
- Study locations
NCT03876106: Completed Phase 1 study of EGFR Inhibitor Induced Acneiform Lesions, sponsored by Lutris Pharma.
NCT03876106 is a Phase 1 study of EGFR Inhibitor Induced Acneiform Lesions that has completed, run by Lutris Pharma. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03876106, a Phase 1 study of EGFR Inhibitor Induced Acneiform Lesions, has completed, sponsored by Lutris Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this phase 1, multicenter study is to evaluate the safety, tolerability and preliminary efficacy of LUT014 in adult metastatic colorectal cancer patients with EGFR Inhibitor induced acneiform lesions
Conditions Studied
Interventions
- DRUG LUT014
Study Locations (6)
Other
- Rabin Medical Center - Petah Tikva
- Sheba Medical Center - Ramat Gan
California
- UCLA Health Santa Monica - Cancer Care - Los Angeles
Missouri
- Washington University School of Medicine-Dermatology - St Louis
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-08-21 |
| Est. Completion | 2020-11-18 |
| Phase | Phase 1 |
What the finished NCT03876106 record still lists
NCT03876106 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with EGFR Inhibitor Induced Acneiform Lesions appearing as the primary indexed condition, and to 1 intervention - of which LUT014 is the first listed.
NCT03876106 lists 6 locations in 5 states (Other, California, Missouri).
Frequently Asked Questions
What is clinical trial NCT03876106 about?
NCT03876106 is a clinical study titled "A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform Lesions". The purpose of this phase 1, multicenter study is to evaluate the safety, tolerability and preliminary efficacy of LUT014 in adult metastatic colorectal cancer patients with EGFR Inhibitor induced acneiform lesions
What is the current status of trial NCT03876106?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-08-21. Estimated completion is 2020-11-18.
What conditions does trial NCT03876106 study?
This clinical trial studies the following conditions: EGFR Inhibitor Induced Acneiform Lesions.
What interventions are being tested in trial NCT03876106?
The interventions under investigation include: LUT014 (DRUG).
Who is sponsoring clinical trial NCT03876106?
This trial is sponsored by Lutris Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03876106 being conducted?
This trial has 6 study locations across California, Missouri, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03876106's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI